Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.cnbc.com/2024/03/27/altimmune-weight-loss-drug-minimized-muscle-mass-loss-in-trial.html
https://www.globenewswire.com/news-release/2024/03/27/2853009/0/en/Altimmune-Announces-Positive-Lean-Mass-Preservation-Data-for-Pemvidutide-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com/news-release/2024/03/20/2849265/0/en/Altimmune-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Business-Update-on-March-27-2024.html
https://seekingalpha.com/article/4673765-altimmune-taking-on-toughest-of-rivals-obesity-unconvinced-recent-rally
https://www.globenewswire.com//news-release/2024/01/02/2802593/0/en/Altimmune-Announces-Presentation-of-Pemvidutide-Clinical-Data-at-Upcoming-NASH-TAG-Conference-on-January-6-2024.html
https://www.globenewswire.com//news-release/2023/11/30/2788970/0/en/Altimmune-Announces-Positive-Topline-Results-from-MOMENTUM-48-Week-Phase-2-Obesity-Trial-of-Pemvidutide.html
https://www.globenewswire.com//news-release/2023/11/07/2774931/0/en/Altimmune-Announces-Third-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com//news-release/2023/10/31/2770039/0/en/Altimmune-to-Report-Third-Quarter-2023-Financial-Results-and-Provide-Business-Update-on-November-7-2023.html
https://www.globenewswire.com//news-release/2023/10/26/2767385/0/en/Altimmune-Granted-Fast-Track-Designation-by-FDA-for-Pemvidutide-for-the-Treatment-of-Non-Alcoholic-Steatohepatitis-NASH.html
https://www.globenewswire.com//news-release/2023/10/25/2766393/0/en/Altimmune-to-Present-New-Data-on-the-Anti-Inflammatory-and-Anti-Fibrotic-Properties-of-Pemvidutide-in-a-Late-Breaking-Presentation-at-The-Liver-Meeting-2023.html